Professur für Innere Medizin (Nephrologie)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine (2021) Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, et al. Journal article Chronic Kidney Disease - Diagnosis and Treatment (2021) Galle J, Schmieder R, Weinreich T Journal article Application of win ratio methodology in the Global SYMPLICITY Registry for patients with atrial fibrillation or obstructive sleep apnea (2021) Mahfoud F, Mancia G, Ukena C, Schmieder R, Narkiewicz K, Ruilope L, Schlaich M, et al. Conference contribution Reasons for antihypertensive medication nonadherence influence physician preferences for hypertension management (2021) Schmieder R, Kandzari DE, Wang TD, Lee YH, Haro C, Pathak A Conference contribution Predictors of blood pressure response after renal denervation beyond pretreatment blood pressure (2021) Schmieder R, Delles C, Lauder L, Ott C, Boehm M, Mahfoud F Conference contribution Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin (2021) Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, et al. Conference contribution Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure (2021) Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, et al. Journal article Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension (2021) Böhm M, Tsioufis K, Kandzari DE, Kario K, Weber MA, Schmieder R, Townsend RR, et al. Journal article Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension (2021) Mahfoud F, Sievert H, Bertog S, Lauder L, Ewen S, Lengele JP, Wojakowski W, et al. Journal article Angiotensin profiles in patients with type 2 diabetes and combination therapy of empagliflozin and linagliptin versus metformin and insulin glargine (2021) Bosch A, Poglitsch M, Kannenkeril D, Ott C, Striepe K, Schmieder R Conference contribution